| P2093 | author name string | Shuang Liu | |
| | Jun Ma | |
| | Guan Wang | |
| | Jeffrey W Taub | |
| | Yubin Ge | |
| | Holly Edwards | |
| | Hai Lin | |
| | Xinyu Li | |
| | Jianyun Zhao | |
| | Yongwei Su | |
| P2860 | cites work | Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia | Q28385690 |
| | Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51 | Q28535006 |
| | mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 |
| | The emerging mechanisms of isoform-specific PI3K signalling | Q29617954 |
| | PI3K and cancer: lessons, challenges and opportunities | Q30080017 |
| | MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies | Q33419789 |
| | Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia | Q33702409 |
| | Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells | Q33831971 |
| | Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. | Q33875554 |
| | Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway | Q34173253 |
| | Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance | Q34466060 |
| | CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells | Q34544769 |
| | Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage | Q35007971 |
| | Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. | Q35374899 |
| | Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. | Q35848677 |
| | Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. | Q36625664 |
| | BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors | Q36866417 |
| | RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. | Q37372829 |
| | Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells | Q37376388 |
| | The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways | Q37420518 |
| | Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells | Q37701599 |
| | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. | Q37865381 |
| | Decoding and unlocking the BCL-2 dependency of cancer cells | Q38115674 |
| | Targeting RAS-ERK signalling in cancer: promises and challenges | Q38272894 |
| | Outlook on PI3K/AKT/mTOR inhibition in acute leukemia | Q38521775 |
| | MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road | Q38591835 |
| | Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer | Q38748709 |
| | GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. | Q40462682 |
| | Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. | Q40626751 |
| | Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. | Q40662652 |
| | Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. | Q41009977 |
| | Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia | Q41206035 |
| | In vivo suppression of Bcl-XL expression facilitates chemotherapy-induced leukaemia cell death in a SCID/NOD-Hu model | Q43548670 |
| | Destabilization of Nav1.7 Sodium Channel α-Subunit mRNA by Constitutive Phosphorylation of Extracellular Signal-Regulated Kinase: Negative Regulation of Steady-State Level of Cell Surface Functional Sodium Channels in Adrenal Chromaffin Cells | Q44403738 |
| | Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia | Q44706243 |
| | PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways | Q45259661 |
| | A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies | Q46195208 |
| | High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. | Q54148841 |
| | Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. | Q54315033 |
| | Detection of mycoplasma contaminations. | Q54702212 |
| | Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C | Q72518867 |
| | Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells | Q89700494 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 13-26 | |
| P577 | publication date | 2017-12-05 | |
| P1433 | published in | Biochemical Pharmacology | Q864229 |
| P1476 | title | Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo | |
| P478 | volume | 148 | |